延长间隔给药可降低那他珠单抗相关PML风险
基于TOUCH数据库35,521例抗JC病毒抗体阳性MS患者的回顾性队列研究显示,与标准间隔给药相比,延长间隔给药与更低的进行性多灶性白质脑病风险相关;主要分析风险比0.06(95%CI 0.01-0.22,p<0.001),相对风险降低94%。
要点
- 那他珠单抗延长间隔给药较标准间隔给药显著降低PML风险。
- 主要分析风险比0.06(95%CI 0.01-0.22),相对风险降低94%。
- 该研究为Class III证据,支持在抗JC病毒抗体阳性MS患者中考虑延长间隔给药。
核心结论
- 那他珠单抗延长间隔给药与标准间隔给药相比,PML风险在临床和统计学上均显著更低。
研究设计与样本
- 回顾性队列研究,纳入TOUCH数据库中截至2017年6月1日的抗JC病毒抗体阳性MS患者35,521例。
- 采用Kaplan-Meier法按既往免疫抑制剂使用分层进行3项计划分析,并用Cox回归校正年龄、性别、既往免疫抑制剂、那他珠单抗起始时间和累计输注次数。
主要发现
- 主要分析中延长间隔给药组1,988例、标准间隔给药组13,132例;PML风险风险比0.06(95%CI 0.01-0.22,p<0.001)。
- 次要分析中延长间隔给药组3,331例、标准间隔给药组15,424例;PML风险风险比0.12(95%CI 0.05-0.29,p<0.001)。
- 主要分析和次要分析的相对风险降低分别为94%和88%,均支持延长间隔给药。
- 第三项分析中延长间隔给药组815例、标准间隔给药组23,168例,延长间隔给药组无PML病例。
关键数值与推荐
- 延长间隔给药组平均给药间隔为35.0至43.0天,标准间隔给药组为29.8至30.5天。
- 主要分析PML风险风险比0.06(95%CI 0.01-0.22,p<0.001),相对风险降低94%。
- 次要分析PML风险风险比0.12(95%CI 0.05-0.29,p<0.001),相对风险降低88%。
临床怎么用
- 对于抗JC病毒抗体阳性的MS患者,可考虑那他珠单抗延长间隔给药以降低PML风险。
- 临床决策时应结合既往免疫抑制剂使用、年龄、性别、那他珠单抗治疗时长和累计输注次数等风险因素综合评估。
局限性
- 本研究为回顾性队列研究,证据等级为Class III。
- 研究基于TOUCH数据库,可能存在登记和随访数据的固有局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). METHODS: This retrospective cohort study included anti-JC virus antibody-positive patients (n = 35,521) in the TOUCH database as of June 1, 2017. The effect of EID on PML risk was evaluated with 3 planned analyses using Kaplan-Meier methods stratified by prior immunosuppressant use. Risk of PML was analyzed by Cox regression adjusted for age, sex, prior immunosuppressants, time since natalizumab initiation, and cumulative number of infusions. RESULTS: This study included 35,521 patients (primary analysis: 1,988 EID, 13,132 SID; secondary analysis: 3,331 EID, 15,424 SID; tertiary analysis: 815 EID, 23,168 SID). Mean average dosing intervals were 35.0 to 43.0 and 29.8 to 30.5 days for the EID and SID cohorts, respectively. Hazard ratios (95% confidence intervals) of PML risk for EID vs SID were 0.06 (0.01-0.22, p < 0.001) and 0.12 (0.05-0.29, p < 0.001) for the primary and secondary analyses, respectively. Relative risk reductions were 94% and 88% in favor of EID for the primary and secondary analyses, respectively. The tertiary analysis included no cases of PML with EID. CONCLUSION: Natalizumab EID is associated with clinically and statistically significantly lower PML risk than SID. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with MS, natalizumab EID is associated with a lower PML risk than SID.
引用
- Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019. PMID: 31515290. doi:10.1212/WNL.0000000000008243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。